EpiVax Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Private

  • Employees
  • 47

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 18

  • Investments
  • 1

EpiVax General Information

Description

Developer of a biotechnology platform designed to create and implement computational immunology tools to benefit the biotechnology industry. The company's platform utilizes scientific and technological assets related to epitope discovery, de-immunization, and vaccine design through a mix of collaborative and internal programs, enabling physicians to have access to immunotherapeutics that offer protection with few side effects.

Contact Information

Website
www.epivax.com
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • 188 Valley Street
  • Suite 424
  • Providence, RI 02909
  • United States
+1 (401)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 188 Valley Street
  • Suite 424
  • Providence, RI 02909
  • United States
+1 (401)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EpiVax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EpiVax‘s full profile, request access.

Request a free trial

EpiVax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to create and implement computational immunology tools to benefit the bio
Drug Discovery
Providence, RI
47 As of 2026

Morristown, NJ
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EpiVax Competitors (1)

One of EpiVax’s competitors is Lonza Biologics, a Corporation company based in Morristown, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lonza Biologics Corporation Morristown, NJ
You’re viewing 1 of 1 competitors. Get the full list »

EpiVax Patents

EpiVax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026101714-A1 Universal t cell targeted influenza vaccine construct Pending 05-Nov-2024
WO-2025024775-A1 Modified interferon-beta-1 having reduced immunogenicity Inactive 26-Jul-2023
WO-2023004307-A1 T cell epitopes and related compositions useful in the prevention and treatment of respiratory syncytial virus infection Inactive 19-Jul-2021
WO-2022251216-A1 T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of beta-coronaviruses Inactive 24-May-2021
WO-2022174151-A1 Prophylactic broad spectrum vaccine for sars-cov-2 Inactive 12-Feb-2021 C07K14/005
To view EpiVax’s complete patent history, request access »

EpiVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EpiVax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EpiVax‘s full profile, request access.

Request a free trial

EpiVax Investments (1)

EpiVax’s most recent deal was a Seed Round with EpiVax Therapeutics for . The deal was made on 25-Sep-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EpiVax Therapeutics 25-Sep-2017 Seed Round Drug Discovery
To view EpiVax’s complete investments history, request access »

EpiVax Exits (1)

EpiVax’s most recent exit was on 25-Sep-2017 from EpiVax Therapeutics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
EpiVax Therapeutics 25-Sep-2017 Completed
To view EpiVax’s complete exits history, request access »

EpiVax FAQs

  • When was EpiVax founded?

    EpiVax was founded in 1998.

  • Where is EpiVax headquartered?

    EpiVax is headquartered in Providence, RI.

  • What is the size of EpiVax?

    EpiVax has 47 total employees.

  • What industry is EpiVax in?

    EpiVax’s primary industry is Drug Discovery.

  • Is EpiVax a private or public company?

    EpiVax is a Private company.

  • What is EpiVax’s current revenue?

    The current revenue for EpiVax is .

  • Who are EpiVax’s investors?

    Escalate Capital Partners and SV Health Investors have invested in EpiVax.

  • Who are EpiVax’s competitors?

    Lonza Biologics is a competitor of EpiVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process